Liver Cancer Forecast in 18 Major Markets to 2027 By Gender and 5-Year Age Cohort

Dublin, March 27, 2017 -- Research and Markets has announced the addition of the "Liver Cancer Forecast in 18 Major Markets 2017-2027" report to their offering.

Liver Cancer, also known as hepatic cancer or primary liver cancer, is a cancer which starts in the cells of the liver. The most common form is hepatocellular carcinoma (HCC) which originates from hepatocytes, the most abundant cell type in the liver, although other cell types in the liver can also become cancerous.

This report provides the current incident population for Liver Cancer across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Liver Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Liver Cancer include:

- Type 2 Diabetes Mellitus
- Liver Cirrhosis
- Hepatitis C
- Hepatitis B

Reasons to Buy

- Able to quantify patient populations in global Liver Cancer's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of Liver Cancer and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Liver Cancer's incident population.
- Identify sub-populations within Liver Cancer which require treatment.
- Gain an understanding of the specific markets that have the largest number of Liver Cancer patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line estimated incidence for Liver Cancer

10. Features of Liver Cancer patients
10.1 AJCC Staging
10.2 Histopathology
10.3 Markers of liver function
10.4 Hepatitis
10.5 Other markers and features of liver cancer

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/zlk5s9/liver_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Oncology Drugs